Merck & Co., Inc. 8-K

What Happened
Merck & Co., Inc. (MRK) filed a Form 8‑K on February 3, 2026 (Item 2.02) to furnish a press release announcing the company's fourth-quarter and full-year 2025 results of operations and financial condition. The 8‑K includes the earnings press release and accompanying supplemental information, which provide the detailed earnings, revenue and other financial results for Q4 and the full year 2025.

Key Details

• Filing date: February 3, 2026; Item reported: 2.02 Results of Operations and Financial Condition.
• Exhibit 99.1: Press release issued February 3, 2026 covering Q4 and year-end 2025 earnings.
• Exhibit 99.2: Supplemental information (detailed schedules/metrics not included in the press release).
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL) for the submission.

Why It Matters
This 8‑K makes Merck’s quarterly and full‑year 2025 earnings, revenue, and related disclosures publicly available; those figures and any management commentary can affect investor decisions and the stock price. Retail investors should review the attached press release and supplemental schedules for revenue, EPS, segment results, and any updated guidance or commentary from management. The full exhibits are available on the SEC EDGAR site and Merck’s investor relations page for detailed numbers.